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Available online xxxxColistin methanesulfonate (CMS) is the only prodrug of colistin available for clinical use for the treatment of in-
fections caused bymultidrug-resistant (MDR) Gram-negative bacteria. Owing to its slow and variable release, an
alternative is urgently required to improve effectiveness. Hereinwe describe a PEGylated colistin prodrugwhere-
by the PEG is attached via a cleavable linker (col-aaPEG) introducing an acetic acid terminatedpoly (ethylene gly-
col) methyl ether (aaPEG) onto the Thr residue of colistin. Due to the labile ester containing link, this prodrug is
converted back into active colistin in vitrowithin 24 h. Compared to CMS, it showed a similar or better antimicro-
bial performance against two MDR isolates of Pseudomonas aeruginosa and Acinetobacter baumannii through in
vitro disk diffusion, broth dilution and time-kill studies. In a mouse infection model, col-aaPEG displayed accept-
able bacterial killing against P. aeruginosa ATCC 27853 and no nephrotoxicity was found after systemic adminis-
tration, suggesting it to be a potential alternative for CMS.







Bacterial infections, especially drug-resistant infections are a major
global health issue [1]. The emergence of multidrug-resistant (MDR)
strains of bacteria and the lack of new antibiotics is a worrying prospect
for all of humanity [2–4]. A recent report suggests failing to control
drug-resistant infections may cause in excess of 10 million deaths per
year and cost up to US$ 100 trillion by 2050 [5]. MDR Gram-negative
bacteria, are particularly difﬁcult to treat due the nature of their robust
outer membrane [6]. Colistin, a lipopeptide and member of the poly-
myxin family, is currently used as a last-line drug for the treatment of
MDR Gram-negative bacterial infections [7–10].
Colistin is a cyclic lipopeptide with an intramolecular hydrophilic
loop with a N-terminal fatty acyl group. The commercial colistin source
contains two major components, colistin A and colistin B, of which the
only difference is on the N-terminal fatty acyl group; a 6-
methyloctanoic acid for colistin A and isooctanoic acid for colistin B
(Fig. 1) [11]. The unique structure of colistin allows it to bind electro-
statically with the bacterial outer membrane and then directly interact
with the lipid A component of the lipopolysaccharide (LPS), the majorniversity of Warwick, Coventry
Haddleton).
. This is an open access article under
celess reversible polymeric c
.doi.org/10.1016/j.jconrel.201constituent of the outer membrane of Gram-negative bacteria [12,13].
The insertion of colistin disrupts the barrier function of the Gram-nega-
tive outer membrane that ultimately results in cell death.
Theﬁve primary amine groups on the 2,4-diaminobutyric acid (Dab)
residues of colistin are essential to this process [13,14]. The protonated
amine groups can recognise and interact with the phosphorylated
sugars on lipid A [13,15,16]. Unfortunately, while often used as a last de-
fence for drug resistant infections this treatment is not allowed for sys-
tematic administration due to its associated nephrotoxicity [7,17].
One avenue to reduce the systemic toxicity of polymyxin is to for-
mulate it into a prodrug form [18]. CMS is the only current FDA ap-
proved prodrug of colistin that can be used intravenously in the clinic
[19]. After themodiﬁcation onﬁve primary amines tomethanesulfonate
groups, CMS is less toxic compared to the native colistin. However, the
slow and variable colistin release rates from the prodrug form compli-
cate its pharmacokinetics, resulting in variable treatment outcomes for
patients [19–21]. A further concerning feature of the prodrug is the het-
erogeneity of themethanesulfonatemodiﬁcationwhich leads to suppli-
er to supplier and batch to batch structural variation in the prodrug
form [22]. Therefore, an alternative prodrug to CMS is highly desirable.
In polypeptide therapeutics, one favoured approach to improve the
pharmacokinetic and pharmacodynamic properties of proteins/pep-
tides is their conjugation to polymers [23–28]. Amongst all polymers
available, FDA approved biocompatible poly (ethylene glycol) (PEG)the CC BY license (http://creativecommons.org/licenses/by/4.0/).
olistin prodrug to combat multidrug-resistant (MDR) gram-negative
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Fig. 1. The chemical structure of the two subgroups of colistin.
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have been best studied and characterised [23,27]. The attachment of
PEG, known as PEGylation, onto those proteins/peptide drugs will help
them bypass the enzymatic recognition, thus prevent them from anti-
genic/immunogenic recognition and proteolytic degradation [27,29,
30]. PEGylation of protein/peptide drugs can also increase the hydrody-
namic volume of the drugs, provide anti-fouling properties, prolonging
their half-life, which can be important to decrease their toxicity to the
kidney and improve patient compliance through longer dosing intervals
[27].
However, a signiﬁcant (or sometimes complete) loss of the protein/
peptide activity has often been reported for many polymer-protein/
peptide conjugates following such modiﬁcations [25,31,32]. This has
mainly been attributed to the blockage of the active site(s) or the altered
structure of the protein/peptide caused by the polymer. Thus, prodrugs
based on traceless and/or reversible conjugations have attracted signif-
icant attention [33–36]. These types of prodrugs usually stay as an inac-
tive or less active derivative under normal (storage) conditions, but can
be converted back to the active drug at the targeted site/environment in
vitro/in vivo. Several dynamic covalent bonds, especially disulphide
bonds have been exploited to build up these releasable linkers [31,35,
37,38]. However, a non-releasable thiol containing spacer was required
to be introduced onto the peptides/proteins that lack free cysteine res-
idue(s). The remaining portion of the linker will sometimes modify
the protein/peptide properties (such as the surface charge or solubility)
and as such, has the potential to result in unwanted side effects,
especially with small peptides. Recently, some other well-designed
fully degradable or cleavable linkers, including 1,6-elimination [34],
thioester [35], bicine [36], and azidomethyl-methylmaleic anhydride
(AzMMMan) [39], were developed to target the more universal amine
containing residues (i.e. lysine residues or a terminal amine) on the pro-
tein/peptide to achieve a traceless recovery of the native protein/
peptide.
In this work, we designed a PEGylated colistin prodrug with a site-
speciﬁc traceless releasable linker exhibiting low toxicity. This gave sim-
ilar or better antibacterial activity to the commercial CMS prodrug. Al-
though it might be considered that it would be more valuable to
investigate reconversion rates under physiological conditions as here
there would be esterases present previous work has looked at colistin
and colistin methanesulfonate in both aqueous media and plasma it
was found that the stability of and release of colistin from the CMS
prodrug were comparable in both PBS buffer and plasma with no evi-
dence of a role for esterases [22]. Instead of modifying the ﬁve Dab res-
idues of colistin as in case of CMS, the two threonine (Thr) residues
were targeted here as it can greatly reduce the site-diversity of themod-
iﬁcation products. A relatively labile ester linkage was chosen to build
up the colistin prodrug using an acetic acid terminated mPEG (aaPEG)
considering the ester is a base and enzyme (i.e. lipase) hydrolysable
bond that can be cleaved easily in the human body. In vitro degradation
studies were performed to investigate colistin release rate. The effect
upon the number of mPEG attachments and different linkages on colis-
tin were also evaluated through the degradation studies. Moreover, thePlease cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201antibacterial activity of the PEGylate colistin prodrugwas systematically
studied through disk diffusion, broth dilution and time-kill experi-
ments. In addition, a mouse thigh infection model was used to compare
the activity performance and toxicity of the PEGylated colistin prodrug
with colistin in vivo.
2. Materials and methods
2.1. Materials
2.1.1. Chemicals
All chemicals were purchased from Sigma-Aldrich and used directly
unless otherwise stated. HPLC solvents are obtained from VWR interna-
tional, LLC. The acetic acid functional mPEG (aaPEG, Mn ~ 2 kDa) was
synthesised based on the previous report [40]. The succinic acid func-
tional mPEG (saPEG,Mn ~ 2 kDa; commercial name: CH₃O-PEG-NHCO-
C₂H₄-COOH; reference number: 122000-3) was purchased from Rapp
Polymere GmbH.
2.1.2. Bacterial strains
Bacterial strains of P. aeruginosa ATCC 27853 and A. baumannii ATCC
19606 (American Type Culture Collection, Manassas, VA) were used in
this study. The strains were stored at−80 °C in a cryovial storage con-
tainer (Simport Plastics, Quebec, Canada). Fresh isolates were
subcultured on Nutrient agar (Media Preparation Unit, The University
of Melbourne, Parkville, Australia) and incubated at 37 °C for 24 h
prior to each experiment. Cation-adjusted Mueller-Hinton broth
(CAMHB; Oxoid, Hampshire, England) was used.
2.2. Methods
2.2.1. Disk diffusion assay
According to the EUCAST guidelines [41], inoculum was
standardised in saline to the density of a McFarland 0.50 ± 0.02 stan-
dard, corresponding to ~108 CFU/mL of each isolate. Freshly prepared
suspension was evenly inoculated onto plates and disks were applied
within 15 min and incubated for 18 h at 37 °C. Plates were examined
for satisfactory streaked suspension and evenly distributed growth to
achieve uniformly circular inhibition zones within the quality control
limits.
2.2.2. Minimum inhibitory concentration (MIC) test
MICswere determined in accordance to the recommendations of the
Clinical and Laboratory Standards Institute [42]. P. aeruginosa ATCC
27853 and A. baumannii ATCC 19606 were used for the tests. Experi-
ments were performed with CAMHB in 96-well polystyrene microtiter
plates. Wells were inoculated with 100 μL of bacterial suspension pre-
pared in CAMHB (containing ∼106 CFU/mL) and 100 μL of CAMHB con-
taining increasing concentrations of colistin, CMS and PEGylated colistin
prodrugs (0–128mg/L). TheMICmeasurements were carried out in du-
plicates with the MIC being deﬁned as the lowest concentration atolistin prodrug to combat multidrug-resistant (MDR) gram-negative
7.02.005
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37 °C.
2.2.3. Time-kill test
The time-kill kinetics of the PEGylated colistin prodrugs at 0.5, 1, and
2 × MIC were examined against A. baumannii ATCC 19606. Brieﬂy, each
test sample was added into a 50 mL Eppendorf tube loaded with 20 mL
of a logarithmic-phase broth culture of approximately 106 CFU/mL to
yield concentrations of 0, 0.5, 1, and 2 × MIC (8 × MIC was also tested
for col-aaPEG2) of the isolate. The tubes were incubated in a shaking
water bath at 37 °C. The samples were taken at 0 min, 30 min and 1,
2, 4, 6 and 24 h. Subcultures for viable counts were performed on nutri-
ent agar (Oxoid) usingWASP2 Spiral Plater (DonWhitley Scientiﬁc) and
incubated at 37 °C for 24 h (48 h for plates with small colonies). Viable
counts were determined by either manual counting or using ProtoCol3
Colony Counter (Don Whitley Scientiﬁc).
2.2.4. In vivo efﬁcacy study using a neutropenic mouse thigh infection
model
All animal experiments were approved by the Monash Institute of
Pharmaceutical Sciences Animal Ethics Committee (ID: MIPS.2010.35)
and were in conductance with the Australian Code for Care and Use of
Animals for Scientiﬁc Purposes (8th Edition 2013).
The polymyxin-susceptible strain P. aeruginosa ATCC 27853was cul-
tured on nutrient agar plates. One colonywas randomly selected and in-
cubated overnight at 37 °C. An aliquot of 0.2 mL of the overnight culture
was dispersed in 20 mL CAMHB and incubated for the production of an
early log-phase culture. Bacteria suspension was concentrated via
centrifugation (3220 ×g for 10min) and the resuspended in 0.9% sterile
saline for inoculation onto mice. The bacterial concentration of
2 × 105 CFU/50 μL per mouse was estimated by determining the optical
density (OD) at 600 nm and conﬁrmed via plating onto agar.
Swiss mice were rendered neutropenic via two intraperitoneally i.p.
doses of cyclophosphamide, 4 days (150mg/kg) and 1 day (100mg/kg)
prior to infection. Thigh infection was established by injecting i.v. bolus
of 50 μL of the bacterial suspension (2 × 105 CFU/50 μL per mouse). So-
lutions for colistin, col-aaPEG and col-aaPEG2were prepared at 1mg/mL
in sterile saline solution (0.9%). At 2 h after inoculation, the mice were
treated with 40 mg colistin base/kg of each compound or the same vol-
ume of saline, respectively, for the control group. At 0 h and 18 h after
administration of either the compound or the control, the animals
were sacriﬁced by an inhalation of isoﬂurane. The skin was disinfected
with 70% ethanol and blood was collected via cardia puncture using a
1 mL syringe rinsed with 5000 IU/mL heparin, diluted serially in sterile
0.9% saline and plated on nutrient agar plates usingWASP2 Spiral Plater
(DonWhitley Scientiﬁc) and incubated at 37 °C for 24 h (48 h for plates
with small colonies). Viable counts were determined by either manual
counting or using ProtoCol3 Colony Counter (Don Whitley Scientiﬁc).
The bacterial load (log10 CFU/mL)was calculated for eachmouse. Exper-
iments were conducted in duplicates and a mean and standard devia-
tion (SD) was calculated.
2.2.5. Measurement of nephrotoxicity in mice
All animal experiments were approved by the Monash Institute of
Pharmaceutical Sciences Animal Ethics Committee. Mice were subcuta-
neously administeredwith either colistin or PEGylated colistin prodrugs
at an accumulated dose of 40 mg colistin base/kg was achieved. At 20 h
after the last dose,micewere euthanized by inhalation of an overdose of
isoﬂurane. Immediately after sampling the blood by cardiac puncture
(above) the right kidney of each mouse was collected and placed into
10% buffered formalin at pH 7.4 (Sigma, Australia) and stored in a
5 mL plastic tube. The formalin-ﬁxed kidneys were subjected to histo-
logical examination at the Australian Phenomics Network, Histopathol-
ogy and Organ Pathology (The University of Melbourne, Parkville,
Australia). Samples were examined by a pathologist who was blind to
the treatment groups. The nature and severity of the histologicalPlease cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201changes was graded as follows: (i) grade 1, mild acute tubular damage
with tubular dilation, prominent nuclei and a few pale tubular casts;
(ii) grade 2, severe acute tubular damage with necrosis; (iii) grade 3,
acute necrosis/infarction.
The overall kidney histology score was calculated as a product of
percentage score and grade score [43]. The SQR score (range: 0–5)
was assigned as follows: (0): no signiﬁcant change; (1): mild damage;
(2): mild to moderate damage; (3): moderate damage; (4): moderate
to severe damage; (5): severe damage.
3. Results and discussion
3.1. Synthesis of reversibly PEGylated colistin
For the site-speciﬁc modiﬁcation of polymyxin we targeted the Thr
residues. However, since the amines of the Dab residues in colistin are
more chemically active than the hydroxyl groups of Thr residues, it
was necessary to ﬁrst protect each of the amine groups prior to the at-
tachment of the polymer. Awell-developed amine-protection approach
using tert-butyloxycarbonyl (Boc) protecting groups was therefore ap-
plied (SFig. 1a). In order to ensure that all the ﬁve amines were fully
protected, an excess of di-tert-butyl dicarbonate (Boc2O) was used
with the addition of potassium carbonate (K2CO3) during themodiﬁca-
tion. The reaction was carried out in a water/tetrahydrofuran (THF)
mixed solvent system to prevent further reaction of Boc2O with the
Thr residues. As commercial colistin has two major components (colis-
tin A and colistin B), a double-peak pattern was observed during high
performance liquid chromatography (HPLC) analysis of the native
lipopeptide (SFig. 1b, black trace). An identical pattern, but at a higher
retention time, was found following reaction with Boc2O, indicating
the protecting groups were successfully introduced onto the amines,
rendering the colistinmuchmore hydrophobic (SFig. 1b, red trace). Fur-
ther, a careful comparison by matrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectrometry (MALDI-ToF MS) of the
modiﬁed polymyxin to the double-peak pattern of native colistin mea-
surements (SFig. 1c), revealed a 500 Damolecular weight increase con-
ﬁrmed that all ﬁve amines were modiﬁed whilst both hydroxyl groups
of the Thr residues remained intact.
The Thr residues on Boc-protected colistin were then PEGylated
using aaPEG via Steglich esteriﬁcation (Fig. 2a). As hydrolysis was to
be used as the mechanism to release the native polymyxin from the
prodrug form, aaPEG was chosen since the electron-withdrawing na-
ture of the oxygen bonded to the α-carbon of the carboxyl group
makes it a better leaving group thus rendering the ester bond formed
less stable and more hydrolytically labile. Since there are two hydroxyl
groups on the Boc5-colistin, two products with different molecular
weight distributions, a mono-mPEG adduct (Boc5-col-aaPEG, Mn
Theory ~ 3.7 kDa, Mn MALDI ~ 3.6 kDa, Fig. 2b) and a bis-mPEG adduct
(Boc5-col-aaPEG2, Mn Theory ~ 5.7 kDa, Mn MALDI ~ 5.5 kDa, Fig. 2c),
were obtained and isolated by HPLC from the reaction mixture at 20–
22 min (SFig. 2b, black trace) and 18–20min (SFig. 2b, green trace), re-
spectively. A polymeric distribution with a typical PEG repeating unit of
44 Da and the double-peak pattern of colistin A and B can be clearly ob-
served from the MALDI-ToF MS data of both adducts (Fig. 2d-e), sug-
gesting the successful attachment of aaPEG onto colistin.
The regeneration of amines on colistin was conducted under
routine conditions for the cleavage of the Boc-protecting groups
(Fig. 2a). After the treatment with 33% TFA in DCM, the more hy-
drophilic deprotected products (col-aaPEG and col-aaPEG2) were
obtained. A successful deprotection was indicated by the clear
shift to a shorter retention time during HPLC characterisation
when c.f. the protected form (SFig. 2b). Moreover, only a slight de-
crease in the molecular weight was observed upon GPC character-
isation (SFig. 2a), suggesting the ester bond between colistin and
aaPEG remained unaffected during deprotection of both conju-
gates. Both col-aaPEG (Mn Theory ~ 3.2 kDa, Mn MALDI ~ 3.2 kDa,olistin prodrug to combat multidrug-resistant (MDR) gram-negative
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Fig. 2. a) The two-step synthesis of the PEGylated colistin conjugates. b)-e) MALDI-ToF MS results of the puriﬁed Boc protected conjugation products, Boc5-col-aaPEG (b) and Boc5-col-
aaPEG2 (c) and the related zoom-in data (d) and (e). f)-g) MALDI-ToF MS of the deprotection products of the mono-modiﬁcation col-aaPEG (f) and double-modiﬁcation col-aaPEG2 (g).
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Fig. 2g) retained the PEG polymeric distribution along with the
colistin double-peak pattern through the MALDI-ToF MS data.
About 500 Da molecular weight decrease was observed for the
deprotected products, further conﬁrming a full recovery of all the
amines on the colistin conjugates.
3.2. The stability and the degradation of the mPEG-colistin conjugates
In order to study the cleavable nature of the ester bond, the degrada-
tion of both PEGylated conjugates was performed in vitro and moni-
tored by HPLC (Fig. 3). To mimic the physiological condition, the test
was conducted at 37 °C in phosphate buffered saline (PBS, pH = 7.4).
For the col-aaPEG form, the signal of the conjugate decreased continu-
ously with a co-committed appearance and increase in the typical colis-
tin double-peaks up to 48 h (Fig. 3b). Noticeably, we found that N75%
colistin can be released from col-aaPEGwithin 6 hwhilst it normally re-
quired N24 h for CMS to achieve a similar extent of colistin release under
similar conditions [22]. The two colistin peaks were then collected and
analysed viaMALDI-ToF MS conﬁrming their identity as native colistin
A and B (Fig. 3d-f). This suggested that the released colistin was chem-
ically unchanged and therefore potentially still active. As for col-aaPEG2,
although the hydrolysis rate is almost twice as slow compared to col-
aaPEG in the ﬁrst 6 h, a similar pattern was observed when following
the reaction by HPLC with the colistin peaks appearing and increasing
as a function of time, leading to full release of colistin within 48 h (Fig.
3c). Interestingly, during degradation a broad peak appeared at 12–
13.5 min, which coincided with the col-aaPEG conjugate. The intensity
of this peak initially increased during the ﬁrst 4 h and then decreased
along with the full consumption of col-aaPEG2 to furnish the native
lipopeptides. This indicates that the release of colistin from col-aaPEG2
undergoes a stepwise degradation process, proceeding via a col-aaPEGPlease cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201as an intermediate product (Fig. 3a). Regardless, this also conﬁrmed
that the two aaPEGs which are attached onto the different Thr residues
can both be hydrolysed during the degradation process to fully liberate
native polymxins.
To investigate the effect of the traceless linker between mPEG and
colistin, a secondPEGylated colistinwith a different ester bondwas syn-
thesised by the sameprotocol using a commercial available succinic acid
terminated mPEG (saPEG) (Fig. 4a). Lacking an electron-withdrawing
oxygen bonded to the α-carbon, saPEG was expected to form a more
stable conjugate. It was observed that colistin can still be released
from both mono- and bis-saPEG modiﬁed products through the same
hydrolysis protocol although the release rate is nearly twice slower
than from the corresponding colistin aaPEG conjugates in the ﬁrst 6 h
(Fig. 4b-c).
A similar degradation study was conducted at ambient temperature
to evaluate the inﬂuence of temperature on the conjugate release
(Fig. 4b-c). As expected, the rate of hydrolysis for all the colistin conju-
gates was retarded compared to those at body temperature. In particu-
lar, the double-modiﬁed conjugates showed much slower release
compared to the mono-adducts due to the stepwise nature of the hy-
drolysis process. All of the results implied that both ester linkers were
temperature sensitive with regards to stability.
3.3. In vitro antimicrobial activity test of the colistin-aaPEG conjugates
The antibiotic activity of the PEGylated conjugateswas subsequently
tested against two different MDR Gram-negative bacteria strains (P.
aeruginosa ATCC 27853 and A. baumannii ATCC 19606). A disk diffusion
assay was ﬁrst conducted using colistin and CMS as positive controls.
The diameter of zone of inhibition (ZoI) of each conjugate is shown in
Table 1. Overall, aaPEG alone showed no antibiotic activity whereas
both aaPEG modiﬁed colistin conjugates showed a clear ZoI. Thisolistin prodrug to combat multidrug-resistant (MDR) gram-negative
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Fig. 3. a) The proposed mechanism of the colistin release from the col-aaPEG2 conjugate. The ability to release the col-aaPEG (b) and col-aaPEG2 (c) conjugate at 37 °C in PBS (1×) buffer
wasmonitored byHPLC. TheMALDI-ToFMS data of the commercial colistin (d) and the isolated colistin peaks (e and f) from the col-aaPEGprodrug solution after the incubation for 2 days.
5C. Zhu et al. / Journal of Controlled Release xxx (2017) xxx–xxxindicated that the colistin conjugates exhibited antimicrobial activity
and crucially that the activity did not occur as a result of the cleaved
polymer but rather, from the released native colistin. Owing to the larg-
er molecular weight and a slower colistin release rate, col-aaPEG2Fig. 4. a) The chemical structures of the aaPEG modiﬁed colistin prodrugs (left) and saPEG mo
double modiﬁed prodrugs (c) from PBS solution. Red lines: aaPEG modiﬁed produrgs (left: co
right: col-saPEG2); solid lines: 37 °C and dotted lines: ambient temperature. (For interpretatio
of this article.)
Please cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201showed a smaller ZOI compared to col-aaPEG at the same loading
amount (20 μg). Conversely, both saPEG modiﬁed colistin conjugates
showed a smaller ZOI compared to the corresponding aaPEG modiﬁed
colistin conjugates which is in agreement with the observed colistindiﬁed ones (right). The colistin release proﬁles of the mono PEGylated prodrugs (b) and
l-aaPEG and right: col-aaPEG2); blue lines: saPEG modiﬁed produrgs (left: col-saPEG and
n of the references to color in this ﬁgure legend, the reader is referred to the web version
olistin prodrug to combat multidrug-resistant (MDR) gram-negative
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Table 1
The diameter of zone of inhibition (ZOI) results of the conjugates against two different Gram-negative bacteria through disk diffusion assay (20 μg, 24 h).
Diameter of zone of inhibition (ZOI) (mm)
Colistin CMS aaPEG col-aaPEG col-aaPEG2 col-saPEG col-saPEG2 milliQ H2O
Pa ATCC 27853 19.0 17.5 0 14.5 9.0 12.5 0 0
Ab ATCC 19606 20.5 19.5 0 13.0 9.5 11.5 0 0
6 C. Zhu et al. / Journal of Controlled Release xxx (2017) xxx–xxxrelease proﬁles. Notably, col-saPEG2 revealed no activity through the
disk diffusion assay, indicating the attachment of PEG inhibited the ac-
tivity of colistin and highlighting the need for a more labile, cleavable
linker for the desired prodrug to maintain its activity over a time scale
relevant to microbial proliferation.
To obtain amore accurate comparison of the relative activities of the
prepared conjugates, minimum inhibitory concentration (MIC) assays
were performed (Table 2). The results revealed that the col-aaPEG con-
jugate behaved similarly to the native colistin in terms of the molar ac-
tivity. This suggests that nearly full cleavage can be achieved from this
colistin conjugate. Furthermore, the released colistin was chemically
identical to native colistin, as conﬁrmed during chemical characterisa-
tion (Fig. 3), and crucially that activity of the released polymxin was
retained. More interestingly, even though the molecular weight of the
col-aaPEG are nearly twice the commercial prodrug CMS (Mn
CMS ~ 1743 g mol−1), less material was required to inhibit the bacteria,
indicating that the colistin release proﬁle of the col-aaPEG prodrug is
more efﬁcient than of CMS in the selected bacteria growth media. In
agreement with the colistin release proﬁles (Fig. 4b) and disk diffusion
assay (Table 1), the col-saPEG conjugate showed a lower activity (2–4
times) than the aaPEG conjugate, highlighting the need for faster colis-
tin release to inhibit the growth of bacteria. Conversely, both double
PEGylated prodrugs exhibited less activity against both bacteria strains
on both mass and molar basis due to the molecular weight of the
prodrugs as well as the slower degradation process. Especially col-
saPEG2 showed no activity in the selected concentration range,
conﬁrming the inhibition of the bacteria growth results from the release
of colistin rather than from the prodrug itself.
In order to determine a better understanding of the killing kinetics of
the prodrug conjugates, time-kill studies were subsequently conducted
by incubating A. baumannii ATCC 19606 bacteria strain as a model with
colistin, CMS and colistin-aaPEG conjugates. The time-kill curves for se-
lected dosage regimen are shown in Fig. 5. Three different doses
(0.5 × MIC, 1 × MIC, and 2 × MIC, referring to mass based MICs of
each compound) were initially tested. At the lower dose (0.5 × MIC),
neither CMS nor aaPEG prodrugs exhibited inhibition with the killing
curves essentially indistinguishable from those of the control, whereas
colistin showed antibacterial killing in the ﬁrst 6 h (Fig. 5a). By increas-
ing the dose to 1 ×MIC and 2 ×MIC of both CMS and col-aaPEG, antimi-
crobial activity was observed with col-aaPEG performing better at both
doses than CMS (Fig. 5b-c). Particularly, col-aaPEG could inhibit the
growth of bacteria to below the detection limit within 30 min at
2 × MIC, whilst it takes 4 h for CMS to control the bacteria growth
close to the detection limit. At all three dosage regimens, col-aaPEG2
did not show any inhibition against the bacteria which is possibly due
to the slower degradation rate compared to the bacteria growth rate.Table 2
The minimum inhibitory concentration of the conjugates against two different Gram-negative
Minimum inhibitory concentration (MIC) (mg/L; μmmol/L)
Colistin CMS aaPEG
Pa ATCC 27853 2; 1.4 8; 4.6 N128; N64
Ab ATCC 19606 1; 0.7 16;9.2 N128; N64
Please cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201However, it still showed an antibacterial killing at 30 min up to 4 h
with regrowth occurring at 24 h when using a higher dose (8 × MIC)
(Fig. 5d, purple trace).3.4. In vivo antimicrobial activity and toxicity evaluation of the colistin-
aaPEG conjugates
Due to the encouraging in vitro performance from the col-aaPEG
prodrugs, the in vivo efﬁcacy of these two labile ester based conjugates
(col-aaPEG and col-aaPEG2) was investigated in comparison to native
colistin treatment against P. aeruginosa ATCC 27853 in a neutropenic
mouse thigh infection model, the gold standard method was employed
[49]. Colistin was employed as the comparator as the highly variable re-
lease and inter-batch heterogeneity of CMS yields large data ﬂuctua-
tions. After 18 h administration of colistin and the aaPEG prodrugs
(40 mg colistin base/kg), a signiﬁcant reduction in the bacterial burden
was observed for both colistin (mean log10 CFU/thigh 0.73 ± 1.46) and
col-aaPEG (mean log10 CFU/thigh 4.77 ± 0.89) compared to the 0 h
(mean log10 CFU/thigh 5.85 ± 0.06, N91.6% bacteria kill). However,
col-aaPEG2 failed to produce sufﬁcient bacterial killing in vivo (mean
log10 CFU/thigh 8.75 ± 0.12). (Fig. 6a)
Nephrotoxicity remains a dose-limiting issue with the broader ap-
plication of polymyxin therapy as it impacts the ability of clinicians to
increase the dose [44–50]. Therefore, in the present study, the in vivo
apoptotic effect of col-aaPEG and col-aaPEG2 was examined through
the histological examination of the kidneys from mice subcutaneously
administered either colistin or PEGylated colistin prodrugs at an accu-
mulateddose of 40mgcolistin base/kg (Fig. 6b). The kidneys ofmice ad-
ministered with the saline control had no observable histological
damage (semi quantitative SQR score of 0, Fig. 6c). In comparison, the
histological examination of the kidneys from the mice treated with co-
listin, col-aaPEG2 showed comparablemild histological damagewith tu-
bule damage, i.e. tubular dilation and degeneration (semi quantitative
SQR score of 1, Fig. 6d, f). Encouragingly, the kidneys of mice treated
with col-aaPEG had no signiﬁcant histological damage and were essen-
tially comparable to the saline control (grade 0 histology kidney scor-
ing; Fig. 6e). These results demonstrate that colistin and col-aaPEG2
(both grade 1 histology kidney scoring) appears to bemore nephrotoxic
than col-aaPEG (Fig. 6). The observation that the doubly PEGylated
prodrug generates more nephrotoxicity than the mono-PEGylated
prodrug is interesting. As the histology assay is well validated it is obvi-
ously not as simple as correlating nephrotoxicity with rates of colistin
release, the observed differences more likely reﬂects the complex and
different renal handling mechanism at play for the mono-PEGylated vs
the doubly PEGylated prodrug [13].bacteria on a weight and molar basis.
col-aaPEG col-aaPEG2 col-saPEG col-saPEG2
4; 1.3 64; 12 16; 5.0 N128; N25
8; 2.5 32; 6.1 16; 5.0 N128; N25
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Fig. 5. In vitro time-kill studies of colistin (a), col-aaPEG (b), CMS (c), col-aaPEG2 (d). The dashed line indicates the lower limit of detection of bacterial growth.
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In this work, fully characterised mono- and bis-mPEG modiﬁed
colistin conjugates with two different ester linkages on the Thr resi-
due(s) of colistin were synthesised via Boc-protection/deprotection
and Steglich esteriﬁcation. All the prodrug candidates were tested
through the in vitro degradation studies and revealed native colistinFig. 6. a) In vivo activity of colistin and prodrugs (col-aaPEG and col-aaPEG2) against P. aerugin
kidney scoring from each sample. c)-f) Microscopic image of the cortex section of the kid
(accumulated dose 40 mg colistin base/kg). c) control (0 h) (SQR score 0); d) colistin (SQR sco
Please cite this article as: C. Zhu, et al., A traceless reversible polymeric c
bacteria, J. Control. Release (2017), http://dx.doi.org/10.1016/j.jconrel.201can be released smoothly from all the colistin conjugates and that the
colistin release rate from the PEGylated conjugates can be altered by
the number of mPEG attachment and the lability of the linker. It is
noted that a full PK study is well beyond the scope of the study and
this would require the development of a validated assay that takes
into account the stability of the prodrug during storage periods and
during assay.osa ATCC 27853 using a mouse thigh infection model. (n = 4). b) Summary of histology
neys of mice treated with saline control, colistin, prodrugs col-aaPEG and col-aaPEG2
re 1); e) col-aaPEG (SQR score 0), f) col-aaPEG2 (SQR score 1).
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8 C. Zhu et al. / Journal of Controlled Release xxx (2017) xxx–xxxStudies also showed the degradation process is temperature sensi-
tive and the prodrugs are relatively stable at ambient temperature.
Among them, the col-aaPEG showed the fastest colistin release rate,
achieving near full colistin release within 24 h, which makes it a viable
prodrug candidate. All in vitro antimicrobial activity tests suggested
col-aaPEG performswith a similar or better activity relative to the com-
mercial prodrug CMS or colistin on both molar and mass basis. In com-
parison to colistin, col-aaPEG showed acceptable bacterial killing in an
in vivo mouse model against P. aeruginosa ATCC 27853 and displayed
no nephrotoxicity through the histological examination of the kidneys.
Although further evaluation is needed to determine whether this activ-
ity proﬁle of col-aaPEG in vivo extends to other Gram-negative species,
we believe that due to the enhanced speciﬁcity conﬁrmed by targeting
Thr residues without loss of antibacterial civility, col-aaPEG has the po-
tential candidate to become a potent alternative prodrug to CMS.
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